[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Catalyst Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100559503","registry-study-to-observe-long-term-safety-of-vamorolone-agamree-in-patients-with-duchenne-muscular-dystrophy-summit-100559503",false,"NCT06564974","Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT","Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy [SUpplemental Patient dMd assessMents Investigating ouTcomes (SUMMIT)]","DMD-001 SUMMIT","Inclusion Criteria:\n\n1. Patient or parent\u002Flegal guardian is willing and able to provide written informed consent once the nature of the registry has been explained and prior to the start of any registry-related procedures.\n2. Patient and\u002For parent\u002Fguardian are willing and able to complete QoL questionnaires.\n3. Male patients at least 2 years old.\n4. Confirmed diagnosis of DMD (via genetic testing or muscle biopsy with absent dystrophin staining to anti- dystrophin antibodies 3, 1, or 2, or dystrophin immunohistochemistry or western blot).\n5. Patient has a current, active prescription for, or is on, AGAMREE®.\n\nExclusion Criteria:\n\n1\\. Any contraindication to AGAMREE® or medical condition, which, in the opinion of the Investigator, would affect registry participation, performance, or interpretation of registry assessments.","MALE","2 Years",{"count":20,"type":21},250,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years and older with Duchenne muscular dystrophy (DMD).",[26],"Duchenne Muscular Dystrophy",[26,28,29,30,31,32],"Neuromuscular","AGAMREE®","Vamorolone","DMD","Muscular Dystrophy","RECRUITING","2026-02-23",{"date":36,"type":37},"2026-02-27","ACTUAL",{"date":39,"type":37},"2024-09-25",{"date":41,"type":21},"2032-02",{"name":43,"class":44},"Catalyst Pharmaceuticals, Inc.","INDUSTRY",27,""]